Published clinical research
The formulation behind Novilora is based on a patented combination of fatty acids and palmitoylethanolamide (PEA) that has been evaluated in published clinical research involving patients experiencing chemotherapy-induced peripheral neuropathy.
146
Patients enrolled
Multi-center
Observational study
Peer-reviewed
Oncology journal
3 months
Evaluation period
Reported
Patient-reported improvements
Three months of evaluation
Patients were assessed at baseline, at each month during the evaluation, and at follow-up.
- 1
Baseline
Initial sensory & motor assessment
- 2
Month 1
Adjustment & early observation
- 3
Month 2
Continued evaluation
- 4
Month 3
Primary endpoint
- 5
Follow-Up
Stabilization assessment
Featured study
The STEFANO Study
A patented fatty acid + PEA formulation evaluated in 146 patients experiencing CIPN. Researchers observed improvements and stabilization of sensory and motor neuropathy symptoms in many patients after three months.
Read the published STEFANO study on PubMed (34496363). See also: an ongoing French clinical trial evaluating this formulation for the prevention of chemotherapy-induced peripheral neuropathy.
Read the STEFANO StudyLibrary
Research downloads
Browse and download published studies and supporting literature as they become available.
Visit Research Library